PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Sun Pharma's Dadra facility receives OAI status from US FDA
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Subscribe To Our Newsletter & Stay Updated
